GLP2R antibody Polyclonal Antibodies Primary antibodies
- Known as:
- GLP2R (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100052
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- GLP2R antibody Polyclonal Antibodies Primary antibodies
Related genes to: GLP2R antibody Polyclonal Antibodies Primary antibodies
- Gene:
- GLP2R NIH gene
- Name:
- glucagon like peptide 2 receptor
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 17p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-02-23
- Date modifiied:
- 2016-10-05
Related products to: GLP2R antibody Polyclonal Antibodies Primary antibodies
Related articles to: GLP2R antibody Polyclonal Antibodies Primary antibodies
- Glucagon-like peptide-2 (GLP-2) has historically been defined by its primary role as an intestinal hormone essential for mucosal growth and epithelial barrier integrity. However, a surge of recent research has sparked a paradigm shift, recasting the GLP-2 receptor (GLP-2R) as a master orchestrator of communication between the gut, brain, and liver. This review synthesizes these advances, highlighting the receptor's strategic expression across this tripartite axis and its functional significance in bidirectional signaling pathways. We also detail its distinct quantitative distribution compared to the GLP-1 receptor (GLP-1R). We examine how GLP-2R serves as a molecular hub in these bidirectional signaling networks critical for both metabolic and cognitive health. Through convergent neural and endocrine pathways, GLP-2R modulates appetite, gastrointestinal motility, metabolic homeostasis, and neuroinflammatory processes that underpin cognitive function. These pathways include vagal afferent circuits, sympathetic innervation, and restricted central access via circumventricular organs. Notably, we also address species-specific differences in GLP-2R function and their critical translational significance for human therapeutics. This is particularly relevant regarding appetite regulation and pancreatic expression. We review the latest pharmacological innovations, including long-acting analogs, synergistic dual agonists, and novel delivery systems. These dual agonists specifically leverage the structural and signaling non-overlap between GLP-1R and GLP-2R to unlock the receptor's full therapeutic potential. Finally, we discuss ongoing challenges and highlight specific unanswered mechanistic questions. This positions GLP-2R as both a promising therapeutic target and a fundamental research tool for dissecting the integrated crosstalk between the gut, brain, and liver that governs whole-body physiology and behavior. - Source: PubMed
Jiang YunuoHan GuoZhang ZixuHu ShengruMu Mingdao - GLP2R has been identified as a downregulated gene in colorectal cancer (CRC) and is correlated with immunocyte infiltration. Herein, we aimed to define the molecular characteristics of GLP2R in CRC, focusing on glycolysis and immune evasion. - Source: PubMed
Publication date: 2026/01/29
Liang DingkongXue FenXie JinkunYang JiyongNi XiaoZhang JingzheGu Honggang - Glucagon-like peptide-2 (GLP-2) has been demonstrated to stimulate bone formation and increase bone mass. Conversely, aberrant expression of fibroblast growth factor 23 (FGF23), a crucial bone-derived hormone that regulates phosphate metabolism and mineralization, is implicated in the pathogenesis of osteoporosis. This study aimed to elucidate the mechanisms by which GLP-2 ameliorates postmenopausal osteoporosis, focusing on whether it exerts bone-protective effects through downregulation of FGF23 expression via the PI3K/AKT/FOXO1 signalling pathway. - Source: PubMed
Publication date: 2026/01/22
Wu KefenRen WeiyingXu Bing'erShen JipingXu KanHu Yu - There is an urgent need for sustainable protein sources to meet rising global nutritional demands. Here, we show that a commercially scalable microbial lysate from Methylococcus capsulatus Bath (McB), used as a dietary protein, orchestrates host-diet-microbe interactions that protect against gastrointestinal inflammation. McB administration rapidly reshapes the gut microbiota and upregulates microbial fermentation pathways, while robustly increasing peripherally induced regulatory T cells (pTregs) across intestinal regions, independent of the microbiota. In contrast, McB-driven induction of tolerogenic Th17 cells requires a functional microbiota with intact fermentation capacity. In models of mucositis and colitis, McB preserves villus architecture, restores mucosal integrity, and reduces disease severity. Mechanistically, these effects depend on microbial fermentation and functional GLP-2 receptor signalling, yet are independent of endogenous GLP-2 secretion, indicating a fermentation-driven molecular mimicry of GLP-2R activation. Collectively, our findings position microbial lysates as a sustainable nutritional strategy that improves gastrointestinal health through defined immune and microbial pathways. - Source: PubMed
Publication date: 2026/01/15
Yang-Jensen Sune KChoi Béatrice S-YNägele Nora SPærregaard Simone INeven KobeSavickas VytautasGupta NazukModvig Ida MHolm Jacob BKristiansen KarstenKissow HannelouiseHolst Jens JHartmann BoletteJensen Benjamin A H - The glucagon-like peptide-2 receptor (GLP-2R) is recognized as a potential target for the treatment of obesity and type 2 diabetes (T2D). Yet, the impact and mechanism of GLP-2R activation on these metabolic traits remain unclear in humans. - Source: PubMed
Publication date: 2026/01/08
Gerlach Peter AGadgaard SarinaMadsen Jakob SLindquist PeterLorente Javier SanchezFaas FelixGabe Maria B NRosenkilde Mette MHauser Alexander S